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The present study describes the antiprotozoal activities of four cyclopalladated compounds, 
[Pd(dmba)(μ-Cl)]2, [Pd(dmba)(NCO)(isn)], [Pd(dmba)(N3)(isn)] and [Pd(dmba)(μ-NCO)]2, 
(dmba: N,N’-dimethylbenzylamine and isn: isonicotinamide), against the diseases leishmaniasis 
(Leishmania amazonensis and Leishmania infantum), Chagas disease (Trypanosoma cruzi) and 
human African trypanosomiasis (Trypanosoma brucei). [Pd(dmba)(μ-NCO)]2 exhibited good 
leishmanicidal and trypanocidal activities against L. amazonensis and T. cruzi intracellular 
amastigote forms, with a 50% inhibitory concentration (IC50) value of less than 9 μM and selectivity 
indexes of 14.47 and 28.42, respectively. Stability essays were conducted in phosphate buffer saline 
(PBS) pH 7.0 and showed that [Pd(dmba)(μ-NCO)]2 is the most stable molecule. These findings 
indicate that this compound presented higher selectivity for these parasites than the other tested 
compounds. The data presented here suggest that this compound should be considered in the 
development of new and more potent drugs for the treatment of leishmaniasis and Chagas disease.
Keywords: cyclopalladated, leishmaniasis, Chagas disease, Leishmania amazonensis, 
Trypanosoma cruzi, trypanosomiasis
Introduction
Leishmanias is ,  Chagas  d isease  (American 
trypanosomiasis, AT) and sleeping sickness (human African 
trypanosomiasis, HAT) are parasitic diseases caused by 
flagellated protozoa related to the family Trypanosomatidae. 
According to the World Health Organization (WHO), 
1.3 million new cases of leishmaniasis and 20,000 to 
30,000 deaths occur annually in all continents,1 7 to 
8 million people are infected worldwide with Chagas 
disease2 and the estimated number of actual cases of HAT 
is currently 30,000.3
More than 20 species of Leishmania4 are responsible 
for different clinical manifestations, including cutaneous 
(CL), mucocutaneous (MCL) and visceral forms (VL).5 
In the Old World, Leishmania major, Leishmania tropica, 
Leishmania aethiopica and some zymodemes from 
Leishmania infantum are the causative agents of CL. 
In the New World, CL is mainly caused by Leishmania 
amazonensis, Leishmania guyanensis, Leishmania 
panamensis and Leishmania braziliensis.6 MCL can be 
caused by L. braziliensis, L. panamensis, L. guyanensis 
and L. amazonensis in the New World and by L. major 
and L. infantum in the Old World.7 Pentavalent antimonial 
drugs are the most frequently prescribed treatments for 
leishmaniasis.8 The main adverse effects that occur in 
systemic administration of these antimonials are arthralgias, 
myalgias, anorexia, and nausea, and other serious side 
effects include pancreatitis, liver-enzyme abnormalities, 
cardiac malfunctions and severe renal toxic effects.9 
Other drugs, such as amphotericin B, pentamidine and 
miltefosine, are second choice drugs but they also produce 
side effects that can endanger the patient’s life.
Trypanosoma cruzi is the causative agent of Chagas 
disease, which is present mainly in Latin America but 
also in North America.10-12 Nifurtimox and benznidazole 
are the only drugs available to treat patients in the acute 
phase of the disease.13,14 However, these drugs are not 
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effective against the chronic phase of the disease, and 
they present multiple side effects, from dermatitis to bone 
marrow depression.15 HAT is caused by Trypanosoma 
brucei gambiense and Trypanosoma brucei rhodesiense.16 
Treatment of the hemolymphatic stage of HAT relies on 
suramin and pentamidine. In the meningoencephalitis 
stage, melarsoprol, a highly toxic arsenic-based drug that is 
effective against both T. b. gambiense and T. b. rhodesiense 
is used. Eflornithine is useful only against T. b. gambiense. 
An eflornithine/nifurtimox combined therapy has been 
used, but this also causes several side effects.17 In summary, 
the conventional drugs that have been employed to 
treat these diseases are antiquated, have high toxicity 
and are ineffective due to drug resistance. Therefore, is 
critical to develop new drugs for the treatment of these 
trypanosomiases.
The use of transition metal-based drugs is increasing 
significantly in the therapy of cancer and tropical diseases; in 
fact, many organometallic compounds have been designed 
to specifically bind to a well-defined target site in different 
biomolecules.18-20 The emergence of drug resistance in 
tropical diseases has led to alternatives to chloroquine 
and its analogues, such as metallocene derivatives for 
the treatment of malaria.19,20 Several scaffolds of metal 
complexes containing palladium, platinum, gold, iridium, 
rhodium, osmium and iron have shown leishmanicidal18-21 
and trypanocidal22,23 activity. For palladium compounds, 
it was recently verified that a cyclopalladated complex 
showed a high selectivity index with trypanocidal activity 
in the treatment of Chagas disease.24 Literature has reported 
a cyclopalladated compound with leishmanicidal activity25 
against L. amazonensis promastigote and amastigote forms; 
and the activity of some palladium(II) cyclometalated 
complexes26 against T. cruzi and Leishmania, which 
indicate on preliminary data that the compounds inhibited 
the growth of intracellular amastigote forms.
Cyclopalladated complexes have high thermodynamic 
and kinetic stability compared to others palladium(II) 
compounds due to the formation of a stable chelate ring.27 
Based on the potential activity of the cyclopalladated 
complexes reported in the literature,28-34 in this study, 
we describe the evaluation of the leishmanicidal and 
trypanocidal activity of [Pd(dmba)(μ-Cl)]2 (1), [Pd(dmba)
(NCO)(isn)] (2), [Pd(dmba)(N3)(isn)] (3) and [Pd(dmba)
(μ-NCO)]2 (4) (Figure 1), dmba: N,N’-dimethylbenzylamine 
and isn: isonicotinamide. All complexes have been 
previously described35-38 but their protozoal activities have 
not been reported yet. 
Herein we tested the above mentioned cyclopalladated 
complexes against L. amazonensis, L. infantum, T. cruzi 
and T. brucei.
Experimental 
Infrared spectra (IR) were recorded on a Spectrum 
2000, PerkinElmer, in the spectral range 4000-370 cm-1. 
Samples were prepared in KBr pellets. 1H and 13C{1H} 
nuclear magnetic resonance (NMR) spectra were referred to 
the high field SiMe4 signal, on a INOVA 500 spectrometer; 
the magnetic field applied was 11.7 T and the resonance 
of 1H and 13C{1H} nucleus were at 500 and 125 MHz, 
respectively. Full spectroscopic data are presented in the 
Supplementary Information section.
The elemental analysis was performed with an 
Elemental Analyzer 2400 CHN, PerkinElmer, at Central 
Analítica, Instituto de Química, USP, São Paulo, Brazil. 
Synthesis of cyclopalladated complexes
All synthesis was carried out at room temperature. All 
reagents were obtained from commercial suppliers and 
used without further purification. 
Compound (1), [Pd(dmba)(μ-Cl)]2 was prepared 
as previously described in the literature,36,37 with some 
modifications. In summary, 22.6 mmol of LiCl (Carlo 
Erba) was added to a solution of 11.3 mmol of PdCl2 
(Degussa S. A.) in methanol. The mixture was stirred 
at 60 °C followed by the addition of 11.3 mmol of 
dmba (N,N’-dimethylbenzylamine, Sigma-Aldrich) and 
14.4 mmol of triethylamine (Carlo Erba). After 6 h, the 
Figure 1. Structures of the cyclopalladated complexes (1)-(4).
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yellow solid formed was filtered off, washed thoroughly 
with methanol and diethyl ether, and dried in vacuo. 
The yield was 90%; mp 185 °C (dec.); anal. calcd. for 
C18H24N2Cl2Pd2: C 39.1, H 4.3, N 5.1; found: C 39.4, H 4.2, 
N 5.0; MW = 552.14.
Compound [Pd(dmba)(μ-NCO)]2 (4) and starting 
species, [Pd(dmba)(μ-N3)]2.H2O, for the synthesis of 
(2) and (3), were prepared based on Almeida et al.35 by 
replacement of chlorido ligands in (1) by the corresponding 
pseudohalides. The reactions were carried out in acetone 
and the obtained yellow solids were filtered off, washed 
with water and pentane, and dried in vacuo. The yield 
was 79% for compound (4) and 87% for the precursor, 
mp 177 °C (dec.), mp 187 °C (dec.), respectively.
[Pd(dmba)(μ-NCO)]2: anal. calcd. for C20H24N4O2Pd2: 
C 42.5, H 4.3, N 9.9; found: C 42.3, H 4.3, N 9.4; 
MW = 552.14.
[Pd(dmba)(μ-N3)]2.H2O: anal. calcd. for C18H24N8Pd2.H2O: 
C 37.1, H 4.5, N 19.2; found: C 37.0, H 4.2, N 18.5; 
MW = 565.28.
Compounds of the type [Pd(dmba)X(isn)]; X = NCO (2), 
N3 (3); isn: isonicotinamide, were prepared according to the 
literature,35,38 with some modifications. 
In summary, compounds (2) and (3) were obtained in 
acetone by reacting the suitable [Pd(dmba)(μ-X)]2 precursor 
with isn (Sigma-Aldrich). The obtained white solids were 
washed thoroughly with acetone and pentane. The yield 
was 90% for compound (2) and 94% for (3), mp 206 °C 
(dec.), mp 196 °C (dec.), respectively. 
[Pd(dmba)(NCO)(isn)] anal. calcd. for C16H18N4O2Pd: 
C 47.5, H 4.5, N 13.8; found: C 47.3, H 4.3, N 13.0; 
MW = 404.76.
[Pd(dmba)(N3)(isn)] anal. calcd. for C15H18N6OPd: 
C 44.5, H 4.5, N 20.8; found: C 44.0, H 4.3, N 20.5; 
MW = 404.76.
Stability assay 
The samples 1- 4
 
were dissolved in acetonitrile (minimum 
amount to solubilize) and the solutions then prepared in 
phosphate buffer saline (PBS) pH 7.0 to give concentrations 
of 317, 312, 220 and 143 μmol L-1. The solutions were 
prepared and the samples were left with occasional stirring 
at room temperature being analyzed aliquots of these 
solutions in the days immediately after the preparation 
(time 0) and after 12, 24, 48 and 72 hours. The experiments 
were performed in HPLC Shimazu LC-20AT CNM-20A 
UV detector SPD-20A using ODS (C-18) column, particle 
size 5 μm, 4.6 × 250 mm, mobile phase: methanol:water 
(70:30, v/v/v), flow 0.8 mL min-1 and λ = 254 nm. For more 
details see Supplementary Information section. 
Biological assays
Compounds 
Cyclopalladated complexes 1, 2, 3, 4 and controls 
(pentamidine, amphotericin B and benznidazole (Sigma-
Aldrich)) were dissolved in DMSO, dimethyl sulfoxide, 
(the highest concentration was 1.4%, which was not 
hazardous to the parasites, as previously determined), added 
to the parasite suspension to final concentrations between 
0.5 and 100.0 μmol L-1.
Parasites: L. amazonensis, L. infantum, T. cruzi and T. brucei 
Promastigotes of L. amazonensis MPRO/BR/1972/
M1841-LV-79 strain and epimastigote forms of T. cruzi 
Y strain39 were maintained at 28 ± 2 ºC in liver-infusion 
tryptose medium (LIT)40 supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) (Gibco). 
Promastigotes of L. infantum (MHOM/BR/72) were freshly 
isolated from golden hamsters (Mesocricetus auratus) 
and maintained at 28 °C in M199 medium (Cultilab) 
without phenol red supplemented with 10% FBS (Gibco), 
penicillin (Sigma-Aldrich) and streptomycin (Sigma-
Aldrich). Promastigote and epimastigote forms cultures 
were carried out until to obtain in the exponential growth 
phase (1.107 parasites mL-1).
Procyclic forms of T. brucei 427 strains41 were cultured 
at 28 ± 2 °C in SDM-79 medium42 containing 10% FBS, 
penicillin (Sigma) and streptomycin (Sigma). Procyclic 
forms cultures were carried out until to obtain the 
exponential growth phase (1.106 parasites mL-1). 
Cytotoxicity using murine macrophages
To determine the cytotoxicity in murine macrophages 
we used a method previously described.43 Adult male Swiss 
albino mice (20 to 35 g) were used in the experiments. 
They were housed in single-sex cages under a 12 h 
light/12 h dark cycle in a controlled-temperature room 
(22 ± 2 °C). The mice had free access to food and water. 
Groups of three animals were used in each test group. The 
experiments were performed in concordance to protocol 
approved by the Institutional Ethics Committee-CEUA 
(Comissão de Ética no Uso de Animais), protocol 
CEUA/FCF/CAr No. 20/2013. The mice were stimulated 
with thioglycolate to collect peritoneal macrophages. 
Murine peritoneal macrophages were seeded in 96-well 
flat-bottom plates (TPP) at a density of 1 × 105 cells per well 
in RPMI 1640 medium44 supplemented with 10% heat-
inactivated FBS, 25 mM HEPES, and 2 mM L glutamine 
and incubated for 4 h at 37 ± 2 °C in a 5% CO2-air mixture. 
The medium was removed, and then new medium was 
added to the cells, which were treated with different 
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concentrations of compounds and controls. Cells without 
drugs were used as a negative control. After that, plates were 
incubated for 24 h at 37 ± 2 °C in a 5% CO2-air mixture. 
Subsequently, the MTT (3-4(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide) colorimetric assay 
was carried out as described further on. Absorbance was 
read in a 96-well plate reader (Robonik) at 595 nm. The 
drug concentration corresponding to 50% of cell growth 
inhibition was expressed as the inhibitory concentration 
(CC50, μM).45
MTT colorimetric assay
L. amazonensis and L. infantum promastigote, T. brucei 
procyclic and T. cruzi epimastigote forms were treated with 
the cyclopalladated complexes and their respective controls 
to calculate the half maximal inhibitory concentration (IC50) 
by MTT colorimetric assay.46,47 The MTT assay is based 
on the determination of the ability of living cells to reduce 
3-4(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT). To avoid interaction of compounds with 
the MTT, the cells were gently washed with PBS before 
the addition of MTT solution on the cells. The compounds 
were tested in different concentrations and incubated at 
28 ± 2 °C for 72 h for L. amazonensis, L. infantum and 
T. cruzi and 24 h for T. brucei.23,43 The assays were carried 
out in triplicates. Absorbance was read in a 96-well plate 
reader (Robonik) at 490 nm for Leishmania species and 
595 nm for T. cruzi and T. brucei. The drug concentration 
corresponding to 50% parasite growth inhibition was 
expressed as the IC50 in μM.
The safety index (SI) was calculated and SI around 
10 means that a compound can be better evaluate for further 
studies. Data obtained were processed with the software 
Origin 7.0.48
Leishmanicidal and trypanocidal activities against 
intracellular amastigote forms
To determine the leishmanicidal and trypanocidal 
activities against intracellular amastigote forms we used 
a method previously described.43 Murine peritoneal 
macrophages were plated at 3 × 105 cells per well on 
coverslips (13 mm diameter) previously arranged in a 
24 well plate in RPMI 1640 medium44 supplemented 
with 10% inactivated FBS and allowed to adhere for 
4 h at 37 ± 2 °C in 5% CO2. Adherent macrophages 
were infected with Leishmania promastigotes in the 
stationary growth phase or T. cruzi trypomastigote using 
a ratio of 5/10:1 parasites per cell (L. amazonensis or 
L. infantum/T. cruzi: macrophages) at 37 °C in 5% CO2 
for 4 h for L. amazonensis, 18 h for L. infantum and 24 h 
for T. cruzi. After that time, the non-internalized parasites 
were removed by washing and infected cultures were 
incubated in RPMI 1640 medium for 24 h at 37 ± 2 °C in 5% 
CO2 to allow parasite multiplication. Then, infected cells 
were treated with different concentrations of compounds, 
amphotericin B (Sigma-Aldrich), pentamidine (Sigma-
Aldrich) or benznidazole (Sigma-Aldrich) for 24 h. The 
cells were then fixed in a methanol solution and stained 
with Giemsa. The number of amastigotes/100 macrophage 
cells and the percent of infected cells were determined. 
The concentration that caused a 50% decrease of growth 
inhibition compared to the control was determined by 
regression analysis and expressed as IC50 in μM.45
The experiments were performed in accordance with the 
protocol approved by the Institutional Ethics Committee-
CEUA (Comissão de Ética no Uso de Animais), protocol 
CEUA/FCF/CAr No. 20/2013.
Differentiation of T. cruzi epimastigote to trypomastigote 
forms
In vitro differentiation of T. cruzi was made as 
previously described in literature.49,50 The epimastigote 
forms were collected from the LIT culture on the 7th day 
when the plateau phase of the growth curve was reached 
and then, re-suspended in artificial triatomine urine (TAU) 
(190 mmol L-1 NaCI, 8 mmol L-1 phosphate buffer, pH 6.0, 
17 mmol L-1 KCl, 2 mmol L-1 CaCI2, 2 mmol L-1 MgCI2), and 
incubated for 2 h at room temperature. The parasites were 
diluted to a final concentration of 5 × 106 parasites mL-1 in 
TAU supplemented with 2.5% (v/v) sodium bicarbonate 
1.4%, 500 units penicillin mL-1, 10 mmol L-1 proline (TAUP 
medium) and incubated at 27 °C for 10 days.
Results and Discussion
Compounds 1-4 (Figure 1) were obtained as stable 
solids (yields ranging from 79% to 94%), and their 
structures are fully supported by infrared spectroscopy (IR) 
and elemental analysis. 
The cyclopalladated complexes were tested against 
L. amazonensis, L. infantum (promastigote and amastigote), 
T. cruzi (epimastigote and amastigote) and T. brucei 
(procyclic forms) using the MTT colorimetric assay44-46 
and an in vitro intracellular amastigote assay43,49,50 to 
evaluate the antiprotozoal activity. Amphotericin B and 
pentamidine were included in the assays as positive 
controls for Leishmania species, benznidazole for T. cruzi 
and pentamidine for T. brucei. The MTT assays were 
carried out after 72 h (L. amazonensis, L. infantum and 
T. cruzi) and 24 h (T. brucei) of incubation. In general, all 
cyclopalladated complexes showed variable leishmanicidal 
and trypanocidal activity. 
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The antiprotozoal effect of the cyclopalladated 
complexes on intracellular amastigotes was evaluated 
in murine peritoneal macrophages obtained from adult 
male Swiss albino mice infected with Leishmania species 
promastigote forms and T. cruzi trypomastigote forms. 
We observed a decrease in the amount of intracellular 
amastigote forms after treatment with the cyclopalladated 
complexes. A cytotoxicity assay was also carried out to 
evaluate the toxicity of the compounds in the peritoneal 
macrophages, showing lower toxic activity on mammalian 
cells. All data are presented in Table 1. 
The ligands dmba and isn by themselves did not 
exhibit antiprotozoal activities (Table 1), suggesting 
that the observed biological activity was due to the 
cyclopalladated complexes. In the present study, we 
observed that compound 2 showed in vitro activity against 
T. cruzi amastigotes (IC50 = 4.45 ± 0.45 μM), while 
compound 4 showed activity against both L. amazonensis 
(IC50 = 9.29 ± 2.08 μM) and T. cruzi amastigotes 
(IC50 = 4.73 ± 1.19 μM). It is interesting to note that for 
L. amazonensis amastigote, compound 4 showed almost 3 
times higher leishmanicidal activity compared to compounds 
2 (IC50 = 22.45 ± 1.17 μM) and 3 (IC50 = 28.82 ± 2.15 μM) 
(Table 1), suggesting that the isn group complexed to 
Pd decreases the anti-Leishmania activity but does not 
influence the anti-T. cruzi activity. 
The replacement of chlorido by the cyanato ligand 
(1 → 4) did not result in any increase in leishmanicidal 
activity against the promastigote and amastigote forms; 
however compound 1 was 2 times more active than 
compound 4 against the T. cruzi epimastigote. On the 
other hand, different efficacy was observed in the T. cruzi 
amastigote form, where compound 4 was approximately 
3 times more active than compound 1. The presence of 
Table 1. Antiparasitic activities (IC50, half-maximal inhibitory concentration, μM), mammalian cell toxicity (CC50, half-maximal cytotoxicity concentration, 
μM) and safety index (SI = CC50/IC50) of the cyclopalladated complexes. The SI values ≥ 10 in bold indicate promising compounds, i.e., those with low 
mammalian toxicity and high toxicity to parasites. Each value is the mean of three experiments performed in triplicate ± standard error
Compound
IC50 (SI) / μM   CC50 / μM
L. infantum L. amazonensis T. cruzi Y T. brucei 427
Macrophage
Promastigote Amastigote Promastigote Amastigote Epimastigote Amastigote Procyclic
1 [Pd(dmba)(μ-Cl)]2 24.72 ± 1.40 
(2.39)
42.00 ± 1.00 
(1.41)
13.53 ± 1.76 
(4.37)
9.57 ± 2.60 
(6.18)
7.06 ± 1.76 
(8.38)
11.82 ± 1.17 
(5.01)
7.14 ± 1.54 
(8.29)
59.18 ± 5.29
2 [Pd(dmba)(NCO)(isn)] 17.54 ± 0.30 
(5.60)
82.30 ± 2.30 
(1.19)
32.12 ± 3.09 
(3.06)
22.45 ± 1.17 
(4.37)
7.72 ± 0.62 
(12.72)
4.45 ± 0.45 
(22.07)
41.56 ± 1.68 
(2.36)
98.22 ± 11.70
3 [Pd(dmba)(N3)(isn)] 12.35 ± 0.30 
(9.56)
59.50 ± 0.80 
(1.98)
25.79 ± 2.20 
(4.58)
28.82 ± 2.15 
(4.10)
14.82 ± 1.09 
(7.97)
3.40 ± 0.26 
(34.73)
46.39 ± 1.17 
(2.55)
118.09 ± 14.67
4 [Pd(dmba)(μ-NCO)]2 16.57 ± 2.10 
(8.11)
53.20 ± 0.10 
(2.53)
13.67 ± 1.54 
(9.83)
9.29 ± 2.08 
(14.47)
11.06 ± 1.76 
(12.16)
4.73 ± 1.19 
(28.42)
16.38 ± 0.70 
(8.21)
134.44 ± 24.53
5 Dmba − − NA NA NA NA NA NA
6 Isn − − NA NA NA NA NA NA
7 Pentamidine 67.71 ± 8.10 
(0.53)
19.77 ± 0.50 
(1.81)
7.62 ± 0.10 
(4.68)
5.07 ± 1.14 
(7.04)
− − 6.44 ± 0.01 
(5.54)
35.69 ± 6.84
8 Benznidazole − − − − 4.07 ± 0.33 
(242.86)
5.28 ± 1.38 
(187.20)
− 988.43 ± 38.10
9 Amphotericin B 0.92 ± 0.01 
(25.11)
2.98 ± 0.40 
(7.75)
3.22 ± 0.03 
(7.17)
4.92 ± 0.14 
(4.70)
− − − 23.10 ± 2.52
NA: not active in the maximal inhibitory concentration tested (100 μmol L-1).
Figure 2. Percentage of viable (a) L. amazonensis promastigote; (b) T. cruzi 
epimastigotes forms treated with the cyclopalladated complexes. 
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NCO instead of Cl in compound 4 increased its chemical 
stability after 72 hours and decrease in its content which 
suggests a profile of Pd release/time without structure 
change (Figure 3). The advantage of compound 4 is its 
effectiveness on amastigotes forms that’s present in human 
host while epimastigotes is present in the bugs. 
All cyclopalladated complexes analyzed showed low 
mammalian toxicity, mainly for compounds 2, 3 and 
4 (CC50 = 98.22, 118.09 and 134.44 μM, respectively) 
compared to pentamidine and amphotericin B (CC50 = 35.69 
and 23.10 μM, respectively). The decrease in cytotoxicity 
of these compounds varies according to their ligands in 
the following order: Cl < NCO (for dimeric compounds), 
NCO < N3 (for mononuclear complexes).
Among the tested complexes, compound 4 showed 
good activity against the selected pathogens as well as 
low toxicity, with SI values of approximately 10 and 
30, except for the L. infantum amastigote. In particular, 
for L. amazonensis promastigote and amastigote forms, 
compound 4 presented SI values of 9.83 and 14.47, 
respectively, which are safer than those of amphotericin B 
(7.17 and 4.70) and pentamidine (4.68 and 7.04).
For T. brucei procyclic forms, we did not observe 
any compound with higher trypanocidal activity than 
pentamidine. However, the compounds 1 and 4 were 
more selective (SI = 8.29 and 8.21, respectively) than 
pentamidine (SI = 5.54).
Cyclopalladated 2, 3 and 4 evaluated against intracellular 
amastigote forms of T. cruzi showed the best SI values 
compared to those obtained for the intracellular amastigote 
forms of the Leishmania species (Table 1). This data 
showed that compounds 2, 3 and 4 were more selective 
for T. cruzi when compared to other parasites. Further 
studies on 3 and 4 are required in order to gain a better 
understanding about their mechanism of action. 
NMR analysis of complexes 2 and 3 were recorded 
in DMSO which indicated that isn is free of its dimeric 
precursors, [Pd(dmba)(μ-N3)]2 and [Pd(dmba)(μ-NCO)]2; 
besides we do not observe species containing DMSO 
coordinated to PdII. According to the literature,51 
cyclopalladated complexes containing pyridine generate 
its corresponding binuclear precursors in solution at room 
temperature. Herein, the mononuclear derivatives of 
cyclopalladated with isn and pseudohalides do not maintain 
their structure completely intact in solution acting possibly 
as a prodrug since we observed anti-T. cruzi activity, 
therefore, the activity of compounds 2 and 3 might be the 
result of fractionation of these species present in solution 
and their precursors. Probably the observed dissociation 
in solution would explain the biological activity of the 
compound and the formation of pro-active species. This 
could contribute to the bioactivity displayed by compound 4. 
This hypothesis can be supported by cisplatin mode of 
action since it undergoes successive hydrolysis reactions 
resulting in active species that react more rapidly with the 
target.52 Further pharmacokinects studies are needed to 
prove the pro-action model of the cyclopalladed compound.
Some authors24 observed that cyclopalladated complex 
against T. cruzi reduced the parasitemia and mortality 
in vivo with very low and nontoxic doses, as well as 
inhibited amastigote intracellular proliferation, similar 
to observed for us in vitro in T. cruzi and L. amazonensis 
intracellular amastigote.
The mechanism of actions proposed by Matsuo et al.24 
suggests that cyclopalladated complex interacts with the 
mitochondria of T. cruzi, causing a collapse in the cell 
extrusion of protons, followed by deoxyribonucleic acid 
(DNA) fragmentation and exposure of phosphatidylserine 
on the surface, a process resembling to apoptosis in 
mammalian cells. Already the same authors mentioned 
that the cyclopalladated complexes are “much more stable 
and less toxic than other derivatives of palladium(II)53 and 
were able to inhibit cathepsin B (CpB)”.54 Other authors55-57 
reported that cathepsin B and L are involved in the growth 
of Leishmania and their virulence in vitro and in vivo. Other 
authors25 observed that a palladacycle compound showed 
inhibition of the cysteine protease activity expressed in 
L. amazonensis amastigotes, being significant the inhibition 
of CpB activity. It was also reported that cyclometalled 
palladium(II) complexes26 inhibited cathepsin B in other 
Leishmania species. However, the compounds did not 
affect the CpB activity of macrophages.25 Probably, for this 
latter reason, our compounds were relatively innocuous on 
Figure 3. Stability study of compound 4. Chromatogram profile of 
compound [Pd(dmba)(μ-NCO)]2 (4) at 0, 12, 24, 48 and 72 hours in 
PBS buffer, pH 7, room temperature, C-18 column, particle size 5 μm, 
4.6 × 250 mm, mobile phase: methanol:water (70:30, v/v/v), flow 
0.8 mL min-1, λ = 254 nm.
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peritoneal macrophages which is very interesting for new 
drugs evaluation. 
Other mechanism of action by palladium complexes58 
described that “the production of oxidative stress as a result 
of their bioreduction and extensive redox cycling”, as well 
as the interaction with DNA.21,56 
Studies on the mechanism of action of cyclopalladated 
complexes 1-4 against both L. amazonensis and T. cruzi are 
underway, and so are the tests with other T. cruzi strains, 
due to genetic variability, to determine if our compounds 
may be following the similar mechanisms of action reported 
in the literature.
Conclusions
The results presented in this work suggest that the 
cyclopalladated compounds 1-4 (in special 4 showed to 
be the most active compound against L. amazonensis 
and T. cruzi intracellular amastigote forms whit low 
cytotoxicity) should be further considered as potential 
new hit in the search for new drugs for the chemotherapy 
of Chagas disease and leishmaniasis. In addition, the 
cyclopalladated 2 and 3 showed a promising anti-T. cruzi 
activity. Our biological results demonstrated that all 
cyclopalladated complexes presented low cytotoxicity 
towards mammalian cells.
Supplementary Information
Supplementary data (IR spectra, 1H NMR spectra, 13C 
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charge at http://jbcs.sbq.org.br as PDF file.
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